Glucon is a start up company developing non-invasive glucose
monitoring devices for the diabetic market. The Glucon devices
will provide continuous, accurate, and real-time glucose monitoring,
for clinical and personal use. It attains blood glucose measurements
directly from inside the blood vessels.
The Glucon devices are based on a novel photoacoustic (optical and
sound-based) technology, and intended to be incorporated into a small,
conveniently wearable instrument. The company believes that Photoacoustics,
a unique combinatorial technology, is superior to optics alone, as it
attains blood glucose measurements directly from inside the blood vessels
and is an improved method both for specificity (identification) and
sensitivity (detection of level changes) of the glucose measurement.
[421-P] Continuous Non Invasive Venous Blood Glucose Monitor
Poster Presented at the 63nd ADA Scientific Session
To view product demo: www.Glucon.com
ITAMAR RAZ, JULIO WAINSTEIN, DALIA ARGAMAN. Jerusalem, Israel; Holon,
Israel; Petach-Tikva, Israel.
Sunday, June 15, 2003, 6:00 PM, Poster Presentation: Clinical
Therapeutics/New Technology – Glucose Monitoring and Sensing (6:00
PM – 7:00 PM)
A novel, non-invasive continuous glucose monitoring device that assess
specifically glucose from within a blood vessel (vein or artery) developed
by Glucon Medical (Petach-Tikva, Israel) was tested on 10 healthy and
7 diabetic individuals, recruited from Hadassah and Wolfson Medical
Centers in Israel. The prototype tested is based on photoacoustic technology.
The photoacoustic effect involves ultrasonic waves created by absorption
of light. These ultrasound waves are generated by illuminating the tissue
with laser pulses at several selected wavelengths. Analysis of the acoustic
signals can map the depth profile of the absorbance of light in the
tissue.
Anatomical structures and interfaces within the in-vivo tissue can be
identified and analyzed independently of each other. Optical wavelengths
are selected to provide specificity to glucose and remove the influence
of other substances present in the blood. Initial measurements on volunteers
were performed while the device was attached to their wrist during 4-6
hours while systemic glucose levels were varied and monitored during
eating and drinking.
At least two high-low variations of the blood glucose level were captured
for each tested subject. In the healthy group, 102 paired data points
were collected using finger stick (FreeStyle – TheraSense) from
10 subjects. The range of glucose levels for the entire population was
68 to 180 mg/dl. Clark error grid analysis showed that 100% of the measurements
fell within zones A and B (87.3% in zone A and 12.7% in zone B). Mean
Absolute Deviation (MAD) was 14.9 mg/dl, and the correlation coefficient
was r= 0.72. In the type I diabetics group, 103 data points were collected
using finger stick from 7 subjects.
The range of glucose levels for the entire population was 100 to 449
mg/dl. Clark error grid analysis showed that 100% of the measurements
fell within zones A and B (88.3% in zone A and 11.7% in zone B). MAD
was 25.0 mg/dl, and the correlation coefficient was r= 0.93. This method
provides an important step towards the implementation of a real-time
accurate fully non-invasive continuous blood glucose monitor.
For a Virtual Demonstration and for more information www.Glucon.com
